Navigation Links
Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Date:11/1/2007

SAN DIEGO, Nov. 1 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced completion of the company's Phase 1 clinical trial of AM103, Amira's internally discovered oral drug candidate for the treatment of inflammatory diseases linked to the leukotriene pathway. Amira also announced the start of a Phase 1 trial for AM803, a second oral drug candidate that targets the same inflammatory response.

AM103 and AM803 are novel inhibitors of 5-lipoxygenase-activiting protein (FLAP) that have demonstrated potential to treat asthma and cardiovascular disease (CVD) by preventing the synthesis of leukotrienes (LT), which trigger inflammation. The recently completed AM103 trial was designed to assess the safety and tolerability of an escalating single dose of the compound and escalating multiple doses in healthy volunteers who received AM103 or placebo for up to 11 days. The trial also assessed the pharmacodynamic properties of AM103, specifically its ability to inhibit LT production.

Results from the Phase 1 trial show that AM103 is safe and well-tolerated at doses up to 1,000 mg per day with no evidence of significant side effects. The systemic exposure of AM103 increased linearly from 50 mg to 1,000 mg.

Pharmacodynamic data demonstrated a robust and statistically significant reduction of LTB4 and LTE4 in a dose-dependent manner. "The results from this trial meet and even exceed our expectations for safety, and provide pharmacodynamic evidence consistent with this mechanism of action," said Peppi Prasit, Amira's chief scientific officer. "The half-life of up to 10 hours also gives us the opportunity to evaluate once-daily dosing in a Phase 2 trial, which we expect to start in 2008."

"Based on this very favorable profile, the excellent tolerability and the high levels of exposure obtained with oral dosing in Phase 1 studies, we are moving forward to conduct a Phase 2 study with AM103 in asthmatic patients," said Bob Baltera, Amira's chief executive
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... management experts at FACE Skincare Medical Wellness are excited ... 3-in-1 Super Facial, specifically designed to increase hydration and ... leaving skin looking radiant. FACE is one of the ... Israel, and the first and only medical spa ... , This innovative treatment uses the unique Oxygeneo™ applicator, ...
(Date:7/24/2014)... Follow us on LinkedIn – ... polyols, is driven by increasing demand from pharmaceuticals, food ... growing awareness over the benefits of consuming alternate sweeteners, ... of the key factors driving growth in the sugar ... the health benefits of sweeteners, consumer adoption is on ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Professional Healthcare at ... announce that Karen Schulkin, a nurse with the company’s Pleasant ... Top 10 Finalist for the 2014 Home Care & Hospice ... for Home Care & Hospice (NAHC). , Annually, NAHC ... and the public to help choose a top home care ...
(Date:7/24/2014)... Maintaining proper oral hygiene is just as important for dogs ... recent years, many different products have become available to dog ... Royal Flush Havanese shares with readers some helpful ... choosing the top products that are the most effective. , ... a dog’s mouth, causing bad breath. This can also lead ...
(Date:7/23/2014)... The beauty products industry is expected ... 2020, according to recent news reports. Creams and oils ... in the U.S. and the CherryNews.com company is now ... is now reviewed at http://cherrynews.com/best-nourishing-eye-serum . , This ... experienced shopper to compare the different brands offered from ...
Breaking Medicine News(10 mins):Health News:FACE Skincare Medical Wellness Debuts Exclusive 3-in-1 Facial Treatment in Michigan 2Health News:Rising Incidence of Diabetes and Obesity Drives the Global Sugar Alcohols Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Diabetes and Obesity Drives the Global Sugar Alcohols Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Professional Healthcare at Home’s Karen Schulkin Named Top 10 Finalist Representing California for 2014 Home Care & Hospice Nurse of the Year 2Health News:Professional Healthcare at Home’s Karen Schulkin Named Top 10 Finalist Representing California for 2014 Home Care & Hospice Nurse of the Year 3Health News:Royal Flush Havanese Reviews Tips on Proper Dental Care For Canines 2Health News:Royal Flush Havanese Reviews Tips on Proper Dental Care For Canines 3Health News:Best Wrinkle Cream Under $100 Reviewed at Top News Website Online 2
... mutations in the p53 tumor-suppressor gene, suggesting the critical ... against cancer. Similarly, roughly 95 percent of cancer-causing mutations ... domain, pointing to this region of the p53 protein ... ,Clearly, a detailed view of the p53 protein in ...
... Victoria Metcalf is out to delve into the Antarctic ... the genetic filter technology// to understand how fish actually ... of the existing connection between fat metabolism and heart ... fat for fuel, unlike humans who get the energy ...
... Health (MOH) says that Singapore will soon conduct a ... Readiness.// , More than 1,000 personnel from ... of Education, the Civil Aviation Authority of Singapore, Immigration ... in the exercise code-named SPARROWHAWK II. , ...
... loss of functions in Alzheimer's patients and found that ... executive ability// is the next to go. ... Clinic. The results of the study presented in the ... cognitive function starts to deteriorate in Alzheimer’s patients they ...
... to 23 students in a post-graduate course by the K ... ,"The division bench of Justice Y R Meena ... administration had not conducted the entrance tests and admission process ... Upadhaya, who argued the case on behalf of two students ...
... that many of the youths working in BPO firms ... ,The experts explained that working continually on ... of the youth. Dr Lim Li Ling, Deputy Director, ... Hospital, said, "Heavy food during night, skipping breakfast, eating ...
Cached Medicine News:Health News:DNA-bound p53 Tumor Suppressor Protein Structure Determined 2
(Date:7/23/2014)... , July 23, 2014 UBM Medica US ... a new online community and information resource for neurologists ... and treat their patients with neurological disorders . ... an aging population, necessitates greater access to dedicated information ... statistics on neurological conditions include: , 1 ...
(Date:7/23/2014)... July 23, 2014 Research and Markets ... (ECG) Market by Product, End-user & by Lead Type ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... into three major segments, namely, holter monitor, resting, and ... valued at $3,683 million in 2013 and is poised ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- The Centers ... new five-state Quality Innovation Network-Quality Improvement Organization (QIN-QIO) contract ... Institute (WVMI). Effective August 1, WVMI will ... West Virginia , Pennsylvania , ... and Louisiana.  The Network will engage providers ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
... NEW YORK, Nov. 10 Reportlinker.com announces ... available in its catalogue. , ... http://www.reportlinker.com/p0161946/Metabolic-Endocrinology-Hypocalcemia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life Science ... on the current drug pipeline. This report ...
... ESTATES, Ill., Nov. 10 Life Spine announced today ... Spinal System. The AVATAR MIS System ... Combining the novel screw delivery system with a ... to accommodate evolving surgical approaches, as well as pathologies ...
Cached Medicine Technology:Reportlinker Adds Metabolic Endocrinology Hypocalcemia 2Reportlinker Adds Metabolic Endocrinology Hypocalcemia 3
The upper body blanket covers the upper torso, arms, neck, and head of the patient....
... air to the patient by way of ... 10C. Cooling the body below the normal ... a therapeutic tool, particularly for the control ... widely used as a treatment for traumatic ...
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
BD Vacutainer® Specialty Tubes - Other - Glass...
Medicine Products: